

---

## Biovica (Q2 Review) - Setback on Timing, not on Long-Term Opportunity

Redeye provides an update on Biovica following the Q2 2025/2026 report, which showed weaker-than-expected sales growth but better cost control than anticipated. In the report, Biovica withdrew its financial targets after key collaborations with Tempus AI and the IDN “Health Giant” were delayed in the quarter. Against this backdrop, we have made several model adjustments, most notably lowering our short- and medium-term sales estimates and increasing our WACC assumption. We revise our fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Biovica \(Q2 Review\) - Setback on Timing, not on Long-Term Opportunity](#)